COMPARISON

MOTS-c vs Plecanatide

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

MOTS-c is authorised or registered in 0 and Plecanatide in 2 of the 10 registers read. MOTS-c: No trial states a phase. Plecanatide: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

MOTS-cPlecanatide
Registered trials
differs
5
clinicaltrials.gov · 2026-10-03
15
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for mots-c
FDA-approved: Trulance Immediate release
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectMOTS-cplaceboPlecanatideplacebo
Diarrhoea--5.8%1.2%
Headache--2.3%1.6%

Trial register MOTS-c: 0 placebo-controlled trials; Plecanatide: 8. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. MOTS-c side effects · Plecanatide side effects

LEGAL STATUS

Approval in each country read

CountryMOTS-cPlecanatideRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerNot on the registerRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerNot on the registerRegulator Swissmedic
BrazilNot on the registerNot on the registerRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeNot on the registerNot on the registerRegulator HSA
TurkeyNot on the registerNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.